Cellectar Biosciences Inc CLRB.OQ CLRB.O is expected to show no change in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Cellectar Biosciences Inc is for a loss of $2.53 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cellectar Biosciences Inc is $84.00, about 96% above its last closing price of $3.35
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -3.60 | -3.90 | -3.39 | Beat | 13.1 |
Mar. 31 2025 | -4.50 | -4.90 | -4.20 | Beat | 14.3 |
Dec. 31 2024 | -10.07 | -10.57 | -1.80 | Beat | 83 |
Sep. 30 2024 | -12.90 | -11.17 | -12.00 | Missed | -7.4 |
Jun. 30 2024 | -9.42 | -10.35 | -0.90 | Beat | 91.3 |
Mar. 31 2024 | -16.74 | -16.90 | -22.20 | Missed | -31.4 |
Dec. 31 2023 | -23.40 | -17.10 | -18.30 | Missed | -7 |
Sep. 30 2023 | -17.62 | -15.75 | -24.90 | Missed | -58.1 |
This summary was machine generated November 5 at 21:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments